This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lunit to Showcase 7 Studies at Asco 2024, Including Ai Innovations in Her2 Quantification, and Multimodal Predictive Models for Immunotherapy Response CI
Lunit Acquires New Zealand's Volpara Health Technologies MT
Lunit Inc. completed the acquisition of Volpara Health Technologies Limited from Harbour Asset Management Limited and others. CI
Volpara to Delist After Court Approves Acquisition by Lunit MT
Lunit Wins Shareholder Approval for Volpara Health Takeover MT
Volpara Health Technologies Secures Approval for Lunit’s Proposed Takeover MT
Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals CI
Lunit Announces Publication of New Study Featuring Lunit SCOPE IO CI
Lunit Announces Two Commercial Deals Signal its Expansion in Europe CI
Lunit Inc. Receives Two Supply Contracts That Mark Its Strategic Expansion into the East and Southeast Asian Region CI
Lunit Announces Three-Year Supply Contract with Samsung Electronics CI
GC Cell Signs Agreement with Lunit for AI-Powered Cancer Treatment MT
Lunit to Take Over Volpara Health; Lunit Shares Decline 4% MT
Lunit Inc. agreed to acquire Volpara Health Technologies Limited from Harbour Asset Management Limited and others for AUD 300 million. CI
Lunit Inc. Partners with NTT DATA Singapore to Introduce Lunit Insight CXR to Singapore's Public Healthcare System CI
Lunit Unveils Prognostic Insights for Colon Cancer - Published in Npj Precision Oncology CI
Lunit Announces to Unveil Eight Groundbreaking Abstracts At the Radiological Society of North America CI
Lunit Inc. Receives U.S. Food and Drug Administration 510(K) Clearance for its 3D Breast Tomosynthesis Ai Solution, Lunit Insight DBT CI
Lunit Expands Reach of Its AI-Powered Chest Screening Solution to Global Military Health Institutions CI
Lunit Inc. Announces Collaborative Study with the Samsung Medical Center Assessed Tumor-Infiltrating Lymphocytes CI
Lunit Enters into Research Collaboration to Explore the Use of AI to Improve the Effectiveness of Immunotherapy CI
New Study Demonstrates Lunit Inc. Scope Io's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes - Findings to Be Presented At the ESMO 2023 CI
Lunit Presents Study on Predicting Treatment Response by HER2 Analysis in Colorectal Cancer CI
Blackford and Lunit Inc Announce Partnership to Enhance Chest and Breast Ai Solution Offering CI
Lunit Accelerates Expansion Across Middle East by Bringing AI Solution to Dr. Sulaiman Al Habib Medical Group CI
Chart Lunit Inc.
More charts
Lunit Inc is a Korea-based company principally engaged in the development and supply of medical software. The Company is principally engaged in the development and supply of medical software such as cancer diagnostic aid solutions, cancer early detection solutions, cancer risk prediction solutions and others through artificial intelligence (AI) technologies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
51,500 KRW
Average target price
100,000 KRW
Spread / Average Target
+94.17%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. A328130 Stock
  4. News Lunit Inc.
  5. Lunit Acquires New Zealand's Volpara Health Technologies